Dallas, TX: ReportsandReports announce it will carry Boehringer Ingelheim GmbH: PharmaVitae Profile Market Research Report in its Store.

Browse complete Boehringer Ingelheim GmbH: PharmaVitae Profile Report

Introduction

This analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical sector. The profile encompasses company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

• Benchmark Boehringer Ingelheim’s performance against key rivals in the prescription pharmaceutical sector
• Evaluate the impact of upcoming patent expiries for Flomax and Sifrol on the company’s outlook
• Track the progress of key new launches including Pradaxa and Ondero, upon which the company is highly reliant

Table of Content

CHAPTER 1 ABOUT THIS PROFILE 2

Executive summary 2

Quarterly news update 2

Company introduction 2

Company sales 2

Company financials 2

Key products and competitors 3

Data sourcing 3

Sales data 3

Analyst consensus 3

CHAPTER 2 EXECUTIVE SUMMARY 4

Key findings 4

Prescription pharmaceutical sales performance, 2001-13 5

Financial performance, 2001-13 6

Boehringer Ingelheim: PharmaVitae forecasts at a glance 7

Strategic insight 8

Leading position in core markets 8

Focused therapeutic coverage following key successes 8

Specialization can restrict opportunities 9

New launches struggle to match the decline of existing products 10

Drag on growth as historical drivers turn to decline 10

Slowing growth highlights challenges beyond 2013 11

External product deals needed to extend growth 12

Historical reliance upon internal discoveries 12

Tougher competition for late-stage product deals 13

SWOT analysis 14

Strengths 14

Weaknesses 16

Opportunities 16

Threats 18

CHAPTER 3 QUARTERLY NEWS UPDATE 20

Key findings 20

Quarterly sales update, Q408 21

Product developments 23

Deals and alliances 26

Product deals 26

Technology deals 26

M&A activity 27

Company announcements 27

Future product milestones 28

CHAPTER 4 COMPANY INTRODUCTION 29

Key findings 29

Background 30

Current corporate structure 31

Prescription pharmaceuticals 31

Consumer healthcare 31

Industrial customer 32

Animal health 32

M&A history 33

CHAPTER 5 COMPANY SALES 34

Key findings 34

Prescription pharmaceutical sales and growth rate analysis, 2001-13 35

Product analysis 37

Product analysis, 2001-07 37

Product analysis, 2007-13 40

Therapy area analysis 44

Therapy area analysis, 2001-07 45

Therapy area analysis, 2007-13 47

Therapy area focus, 2001-13 50

Geographic analysis 52

Geographic analysis, 2001-07 53

Geographic analysis, 2007-13 54

Geographic focus, 2001-13 56

Launch/core/expiry analysis 58

Explanation of launch/core/expiry analysis 58

Launch analysis, 2007-13 59

Core analysis, 2007-13 62

Expiry analysis, 2007-13 64

Launch/core/expiry configuration, 2007-13 65

Molecule type analysis 68

Molecule type analysis, 2001-07 69

Molecule type analysis, 2007-13 70

Externalization analysis 73

Externalization analysis, 2001-07 74

Externalization analysis, 2007-13 76

CHAPTER 6 COMPANY FINANCIALS 80

Key findings 80

Reconciliation between PharmaVitae-formatted prescription pharma sales and company reported total sales, 2001-07 81

Financial statements, 2001-07 82

Profit and loss account, 2001-07 82

CHAPTER 7 KEY PRODUCTS AND COMPETITORS 84

Key findings 84

Overview 85

Respiratory 86

Spiriva franchise 86

Overview 86

Sales forecast 87

Success driven by unique market position 87

Cardiovascular 89

Micardis franchise 89

Overview 89

Sales forecast 90

Uptake driven by best in class attributes 90

Growth maintained despite competition across 2007-13 91

Pradaxa 92

Overview 92

Sales forecast 93

Uptake driven by unmet need 93

Pradaxa may be adversely affected by DTI history 94

Competition will prevent a greater capture of market share 95

Urology & gender specific health 96

Flomax 96

Overview 96

Sales forecast 97

Market leading BPH treatment 97

Generic erosion dependent upon acheivment of pediatric exclusivity 98

Central nervous system 99

Sifrol/ Mirapex 99

Overview 99

Sales forecast 100

Historically positioned as a market leading treatment for Parkinson’s disease 100

Late entry to once-daily market limits sales potential 101

CHAPTER 8 APPENDIX 103

R&D pipeline 103

References 111

Abbreviations 111

Exchange rates 112

Browse complete Boehringer Ingelheim GmbH: PharmaVitae Profile Report

Browse all Healthcare Market Research Reports

Browse all Datamonitor Market Research Reports RSS

Browse all Latest Report

Related Reports:

Boehringer Ingelheim GmbH Market Share Analysis

Boehringer Ingelheim GmbH-Company Report

Boehringer Ingelheim GmbH – SWOT Analysis

About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/